Clinical trial
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
NCT00054314 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00054314 |
|---|---|
| Title | BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer |
| Official title | An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC) |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | ortataxel |
| Start date | Mar 1, 2002 |
| Primary completion | Apr 1, 2003 |
| First posted | Feb 6, 2003 |
| Last update posted | Sep 26, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: